Ministry of Defence, Defence Science and Technology Laboratory
The Development, Validation and Supply of Physostigmine Free Base
The procurement contact named on the official notice.
The submission route named on the official notice.
This is a large award for Medical Equipment & Pharmaceuticals — above three-quarters of comparable contracts. Based on 9,456 valued Medical Equipment & Pharmaceuticals tenders in our corpus.
We haven’t measured a rhythm for Ministry of Defence, Defence Science and Technology Laboratory in Medical Equipment & Pharmaceuticals yet — so we’re not going to guess at one.
The Ministry of Defence (MoD) is inviting expressions of interest for a requirement for the provision of Physostigmine Free Base(also known as eserine; chemical name 1,2,3,3aβ,8,8aβ-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b] indol-5-yl-methylcarbamate; chemical formula C15H21N3O2; molecular weight 275,36 g/mol). as part of an ongoing product development and anticipated commercialisation.
The initial Physostigmine supplied must be suitable for use in a pivotal Phase I clinical setting and the manufacturing process will produce material which does not add additional non-clinical activities to the overall programme, best endeavours should be taken to remove processing impurities.
The Supplier is to develop, scale-up and validate the manufacturing method for Physostigmine Free Base as an Active Pharmaceutical Ingredient (API) for use in a MoD final medicinal product currently under development.
The API must be developed and manufactured according to Good Manufacturing Practice (GMP) and must conform to European Transmissible Spongiform Encephalopathies (TSE) requirements, developed such that Intellectual property (IP) is vested in the Authority.
The Authority intends to seek a Marketing Authorisation for the final medicinal product from the Medicines and Healthcare products Regulatory Agency (MHRA) and Physostigmine will be required as an active ingredient for a future registered medicinal product.
The Supplier is required to provide information necessary for the Authority to complete the Chemistry, Manufacturing and Control (CMC) documentation to support a Clinical Trial Application (CTA) and Marketing Authorisation Application for the final medicinal product and make this documentation available to the MA applicant in an appropriate format for inclusion within CTD Module 3.
The Authority anticipates a Limited Quality by Design (QBD) approach to the manufacturing process as defined by the International Conference on Harmonisation (ICH).
All procurement documents are accessible via www.contracts.mod.uk Quantity or scope: The Contract has an expected duration of 10 years (120 months), plus 5 option years (60 months).
Option years may be taken up consecutively or concurrently (to be determined).
What the notice asks for
The initial Physostigmine supplied must be suitable
The initial Physostigmine supplied must be suitable for use in a pivotal Phase I clinical setting and the manufacturing process will produce material which does not add additional non-clinical activities to the overall programme, best endeavours should be taken to remove processing impurities.
The API must be developed and manufactured
The API must be developed and manufactured according to Good Manufacturing Practice (GMP) and must conform to European Transmissible Spongiform Encephalopathies (TSE) requirements, developed such that Intellectual property (IP) is vested in the Authority.
Sentences from the notice that state an obligation, surfaced automatically and shown in the order they appear. Not an exhaustive list — always confirm against the tender documents.
What this notice demands of you
1 named, none in explicit obligation language. Each one is quoted from the notice.
The Authority intends to seek a Marketing Authorisation for the final medicinal product from the Medicines and Healthcare products Regulatory Agency (MHRA) and Physostigmine will be required as an active ingredient for a future registered medicinal product.
Matched against the notice text, so this is a floor — the tender pack will demand things the notice never mentions. “Says must” means the quoted sentence itself used obligation language; anything ambiguous is left as a mention.
Make the case to bid
Reveal who to approach at Ministry of Defence, Defence Science and Technology Laboratory, and generate a go-to-market strategy from their news, accounts and people.
Free to start. Named contacts come from published notices; the strategy is generated from the buyer’s news, accounts and people.
The full intelligence dossier
Our agent reads Ministry of Defence, Defence Science and Technology Laboratory’s accounts, hunts live signals, finds the people who decide — and hands you a bid strategy plus a go-to-market influence plan, including what your team should post this week. You approve every paid step.
Five included while we’re in beta, and the agent asks before it spends on any paid step.
- OCID
- ocds-h6vhtk-03b6c1
- Stage
- tender · Open
- Source
- Find a Tender
- Buyer ref
- 009030-2023
Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.
Who wins this kind of work
The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.
Top suppliers & buyers in Medical Equipment & Pharmaceuticals
Ministry of Defence, Defence Science and Technology Laboratory’s tender network
Similar open tenders
The Supply of Sterilisation Products
University Hospitals of North Midlands NHS Trust
ID 6636040 - DoJ - NIPS - Supply and Delivery of Challenging Environment Furniture 2026
Northern Ireland Prison Service